Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis

References

• International Rhinitis Management Working Group. international consensus report on the diagnosis and management of rhinitis. Allergy. 1994;49(19 Suppl):1–34.
   Google Scholar
• Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81(5 Pt 2):463–468.
   PubMed Web of Science ®Google Scholar
• Saleh HA, Durham SR. Perennial rhinitis. BMJ. 2007;335(7618):502–507.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Valero A, Ferrer M, Sastre J, et al. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007;120(2):359–365.
   PubMed Web of Science ®Google Scholar
• Montoro J, Del Cuvillo A, Mullol J, et al. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. Allergy. 2012;67(11):1437–1442.
   PubMed Web of Science ®Google Scholar
• Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005;60(3):350–353.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Bousquet-Rouanet L, Co Minh HB, et al. ARIA (Allergic Rhinitis and Its Impact on Asthma) classification of allergic rhinitis severity in clinical practice in France. Int Arch Allergy Immunol. 2007;143(3):163–169.
   PubMed Web of Science ®Google Scholar
• Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–494.
   PubMed Web of Science ®Google Scholar
• Demoly P, Allaert FA, Lecasble M, et al. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003;58(7):672–675.
   PubMed Web of Science ®Google Scholar
• Navarro A, Colas C, Anton E, et al. Epidemiology of allergic rhinitis in allergy consultations in Spain: Alergologica-2005. J Investig Allergol Clin Immunol. 2009;19(Suppl 2):7–13.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 2008;29(6):600–608.
   PubMed Web of Science ®Google Scholar
• Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl):S2–S8.
   Google Scholar
• Jessen M, Malm L. Definition, prevalence and development of nasal obstruction. Allergy. 1997;52(40 Suppl):3–6.
   PubMed Web of Science ®Google Scholar
• Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86(5):494–507. quiz 507–8.
   PubMed Web of Science ®Google Scholar
• Varonier HS, De Haller J, Schopfer C. Prevalence of allergies in children and adolescents. Helv Paediatr Acta. 1984;39(2):129–136.
   PubMedGoogle Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764.
   PubMed Web of Science ®Google Scholar
• Georgalas C, Vlastos I, Picavet V, et al. Is chronic rhinosinusitis related to allergic rhinitis in adults and children? Applying epidemiological guidelines for causation. Allergy. 2014;69(7):828–833.
   PubMed Web of Science ®Google Scholar
• Prokopakis EP, Vlastos IM, Ferguson BJ, et al. SCUAD and chronic rhinosinusitis. Reinforcing hypothesis driven research in difficult cases. Rhinology. 2014;52(1):3–8.
   PubMed Web of Science ®Google Scholar
• Prokopakis EP, Kalogjera L, Karatzanis AD. Pediatric Severe Chronic Upper Airway Disease (P-SCUAD). Curr Allergy Asthma Rep. 2015;15(12):68.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666–668 e1–e5.
   Google Scholar
• Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94(2 Pt 1):182–188.
   PubMed Web of Science ®Google Scholar
• Camelo-Nunes IC, Sole D. Allergic rhinitis: indicators of quality of life. J Bras Pneumol. 2010;36(1):124–133.
   PubMed Web of Science ®Google Scholar
• Blaiss M, Philpot E. A study to determine the impact of rhinitis on sufferers sleep and daily routine. J Allergy Clin Immunol. 2005;115(2 Suppl):S197.
   Google Scholar
• Rimmer J, Downie S, Bartlett DJ, et al. Sleep disturbance in persistent allergic rhinitis measured using actigraphy. Ann Allergy Asthma Immunol. 2009;103(3):190–194.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000;25(6):551–557.
   PubMed Web of Science ®Google Scholar
• Moll B, Klimek L, Eggers G, et al. Comparison of olfactory function in patients with seasonal and perennial allergic rhinitis. Allergy. 1998;53(3):297–301.
   PubMed Web of Science ®Google Scholar
• Bavbek S, Kumbasar H, Tugcu H, et al. Psychological status of patients with seasonal and perennial allergic rhinitis. J Investig Allergol Clin Immunol. 2002;12(3):204–210.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25.
   PubMed Web of Science ®Google Scholar
• Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62(Suppl 85):9–16.
   PubMed Web of Science ®Google Scholar
• Han DH, Rhee, C-S. Comorbidities of allergic rhinitis, allergic diseases - highlights in the clinic, mechanisms and treatment. Pereira C, editor. 2012. ISBN: 978-953-51-0227-4, InTech.
   Google Scholar
• Ghaffari J, Abbaskhanian A, Jalili M, et al. IQ score of children with persistent or perennial allergic rhinitis: a comparison with healthy children. Iran J Child Neurol. 2014;8(3):44–48.
   PubMedGoogle Scholar
• Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 2010;31(5):375–380.
   PubMed Web of Science ®Google Scholar
• Crown WH, Olufade A, Smith MW, et al. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health. 2003;6(4):448–456.
   PubMed Web of Science ®Google Scholar
• Min YG, Choi BY, Kwon SK, et al. Multicenter study on the prevalence of perennial allergic rhinitis and allergy-associated disorders. J Korean Med Sci. 2001;16(6):697–701.
   PubMed Web of Science ®Google Scholar
• Riccioni G, Della Vecchia R, Castronuovo M, et al. Bronchial hyperresponsiveness in adults with seasonal and perennial rhinitis: is there a link for asthma and rhinitis? Int J Immunopathol Pharmacol. 2002;15(1):69–74.
   PubMed Web of Science ®Google Scholar
• Ibanez MD, Valero AL, Montoro J, et al. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain. Pediatr Allergy Immunol. 2013;24(7):678–684.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Annesi-Maesano I, Carat F, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35(6):728–732.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–S84.
   Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 Suppl):S1–S43.
   Google Scholar
• Bousquet J, Reid J, van Weel C, et al. Allergic Rhinitis management pocket reference. Allergy. 2008;63:990–996.
   Google Scholar
• Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011;4(3 Suppl):S22–S27.
   Google Scholar
• Skoner DP, LaForce CF, Nathan RA, et al. Effect of cetirizine on symptom severity and quality of life in perennial allergic rhinitis. Allergy Asthma Proc. 2014;35(4):338–345.
   PubMed Web of Science ®Google Scholar
• Freche C, Leynadier F, Horak F, et al. Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Ann Allergy Asthma Immunol. 2002;89(3):304–310.
   PubMed Web of Science ®Google Scholar
• Simons FE, Prenner BM, Finn A Jr., et al. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111(3):617–622.
   PubMed Web of Science ®Google Scholar
• Kim K, Sussman G, Hebert J, et al. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96(3):460–465.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Ansotegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012;28(1):131–139.
   PubMed Web of Science ®Google Scholar
• Sastre J, Mullol J, Valero A, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012;28(1):121–130.
   PubMed Web of Science ®Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70(Suppl 100):1–24.
   PubMed Web of Science ®Google Scholar
• Marmouz F, Giralt J, Izquierdo I. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J Asthma Allergy. 2011;4:27–35.
   PubMedGoogle Scholar
• Pasquali M, Baiardini I, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36(9):1161–1167.
   PubMed Web of Science ®Google Scholar
• Walter Canonica G, Bousquet J, Van Hammee G, et al. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med. 2006;100(10):1706–1715.
   PubMed Web of Science ®Google Scholar
• Mullol J, Bachert C, Bousquet J. Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine. Ther Clin Risk Manag. 2005;1(4):265–271.
   PubMedGoogle Scholar
• Bousquet J, Demarteau N, Mullol J, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005;60(6):788–794.
   PubMed Web of Science ®Google Scholar
• Guilemany JM, Garcia-Pinero A, Alobid I, et al. The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). Int Arch Allergy Immunol. 2012;158(2):184–190.
   PubMed Web of Science ®Google Scholar
• Kulapaditharom B, Pornprasertsuk K, Boonkitticharoen V. Clinical assessment of levocetirizine and budesonide in treatment of persistent allergic rhinitis regarding to symptom severity. J Med Assoc Thai. 2010;93(2):215–223.
   PubMedGoogle Scholar
• Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study. Pediatr Allergy Immunol. 2013;24(2):144–150.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I. Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study. J Biol Regul Homeost Agents. 2010;24(2):177–183.
   PubMed Web of Science ®Google Scholar
• Grossman J, Halverson PC, Meltzer EO, et al. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy. 1994;73(2):141–146.
   PubMedGoogle Scholar
• Gastpar H, Nolte D, Aurich R, et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy. 1994;49(3):152–158.
   PubMed Web of Science ®Google Scholar
• Herman D, Garay R, Le Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol. 1997;39(1):1–8.
   PubMed Web of Science ®Google Scholar
• Gawlik R, Jawor B, Rogala B, et al. Effect of intranasal azelastine on substance P release in perennial nonallergic rhinitis patients. Am J Rhinol Allergy. 2013;27(6):514–516.
   PubMed Web of Science ®Google Scholar
• Okubo K, Okuda M, Magara H, et al. Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Curr Med Res Opin. 2010;26(7):1657–1665.
   PubMed Web of Science ®Google Scholar
• Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581–2587.
   PubMed Web of Science ®Google Scholar
• Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology. 1993;31(4):169–174.
   PubMedGoogle Scholar
• Scadding GK, Lund VJ, Jacques LA, et al. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy. 1995;25(8):737–743.
   PubMed Web of Science ®Google Scholar
• Van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol. 1993;91(6):1146–1154.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Scadding GK. Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis. Pediatr Allergy Immunol. 2004;15(3):261–266.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(5):497–505.
   PubMed Web of Science ®Google Scholar
• Okubo K, Okamasa A, Honma G, et al. Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: a multicentre, open-label trial. Allergol Int. 2015;64(1):60–65.
   PubMed Web of Science ®Google Scholar
• Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007;62(9):1071–1077.
   PubMed Web of Science ®Google Scholar
• Maspero JF, Rosenblut A, Finn A Jr., et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138(1):30–37.
   PubMed Web of Science ®Google Scholar
• Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol. 1997;79(4):370–378.
   PubMed Web of Science ®Google Scholar
• Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2): E22.
   PubMed Web of Science ®Google Scholar
• Hadley JA,KM, Jb A, Pien LC. Diagnosis and management of rhinitis and rhinosinusitis. Vol. 65. 3rd ed. New York: Professional Communications Inc; 2005.
   Google Scholar
• Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81(2):128–134.
   PubMed Web of Science ®Google Scholar
• Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 1998;102(6 Pt 1):902–908.
   PubMed Web of Science ®Google Scholar
• Stahl E, Van Rompay W, Wang EC, et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2000;84(4):397–402.
   PubMed Web of Science ®Google Scholar
• Rinne J, Simola M, Malmberg H, et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol. 2002;109(3):426–432.
   PubMed Web of Science ®Google Scholar
• Catana IV, Chirila M, Negoias S, et al. Effects of corticosteroids on hyposmia in persistent allergic rhinitis. Clujul Med. 2013;86(2):117–120.
   PubMedGoogle Scholar
• Wandalsen GF, Mendes AI, Sole D. Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy. 2010;24(1):e32–e36.
   Google Scholar
• Vaidyanathan S, Barnes M, Lipworth BJ. Comparative safety and efficacy of 2 formulations of fluticasone aqueous nasal spray in persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2009;102(1):76–83.
   PubMed Web of Science ®Google Scholar
• Han D, Liu S, Zhang Y, et al. Efficacy and safety of fluticasone furoate nasal spray in Chinese adult and adolescent subjects with intermittent or persistent allergic rhinitis. Allergy Asthma Proc. 2011;32(6):472–481.
   PubMed Web of Science ®Google Scholar
• Baiardini I, Villa E, Rogkakou A, et al. Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy. 2011;41(3):417–423.
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Melli V, et al. Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother. 2014;15(1):73–83.
   PubMed Web of Science ®Google Scholar
• Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(6):551–557.
   PubMed Web of Science ®Google Scholar
• Philip G, Williams-Herman D, Patel P, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007;28(3):296–304.
   PubMed Web of Science ®Google Scholar
• Santos CB, Hanks C, McCann J, et al. The role of montelukast on perennial allergic rhinitis and associated sleep disturbances and daytime somnolence. Allergy Asthma Proc. 2008;29(2):140–145.
   PubMed Web of Science ®Google Scholar
• Sardana N, Santos C, Lehman E, et al. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Asthma Proc. 2010;31(1):5–9.
   PubMed Web of Science ®Google Scholar
• Ciebiada M, Ciebiada MG, Kmiecik T, et al. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. J Investig Allergol Clin Immunol. 2008;18(5):343–349.
   PubMed Web of Science ®Google Scholar
• Cingi C, Ozlugedik S. Effects of montelukast on quality of life in patients with persistent allergic rhinitis. Otolaryngol Head Neck Surg. 2010;142(5):654–658.
   PubMed Web of Science ®Google Scholar
• Ciebiada M, Gorska-Ciebiada M, Barylski M, et al. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25(1):e1–e6.
   Google Scholar
• Ratner PH, Ehrlich PM, Fineman SM, et al. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc. 2002;77(4):350–354.
   PubMed Web of Science ®Google Scholar
• Wilson II, Coombes JA. Rynacrom (sodium cromoglycate) in intractable perennial rhinitis. N Z Med J. 1975;82(550):265–266.
   PubMed Web of Science ®Google Scholar
• Cohan RH, Bloom FL, Rhoades RB, et al. Treatment of perennial allergic rhinitis with cromolyn sodium. Double-blind study on 34 adult patients. J Allergy Clin Immunol. 1976;58(1 PT. 2):121–128.
   PubMed Web of Science ®Google Scholar
• McDowell MK, Spitz E. Treatment of chronic perennial allergic rhinitis: a double-blind trial of cromolyn sodium. Ann Allergy. 1977;39(3):169–174.
   PubMedGoogle Scholar
• Sorri M, Jokinen K, Palva A. Disodium chromoglycate therapy in perennial rhinitis. Acta Otolaryngol Suppl. 1979;360:30–32.
   PubMedGoogle Scholar
• Lejeune M, Lefebvre PP, Delvenne P, et al. Nasal sodium cromoglycate (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: a preliminary study. Int Immunopharmacol. 2015;26(1):272–276.
   PubMed Web of Science ®Google Scholar
• Sherkat AA, Sardana N, Safaee S, et al. The role of pseudoephedrine on daytime somnolence in patients suffering from perennial allergic rhinitis (PAR). Ann Allergy Asthma Immunol. 2011;106(2):97–102.
   PubMed Web of Science ®Google Scholar
• Baroody FM, Brown D, Gavanescu L, et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2011;127(4):927–934.
   PubMed Web of Science ®Google Scholar
• Barnes ML, Biallosterski BT, Gray RD, et al. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology. 2005;43(4):291–295.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Orgel HA, Bronsky EA, et al. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol. 1992;90(2):242–249.
   PubMed Web of Science ®Google Scholar
• Druce HM, Spector SL, Fireman P, et al. Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. Ann Allergy. 1992;69(1):53–60.
   PubMedGoogle Scholar
• Finn AF Jr., Aaronson D, Korenblat P, et al. Ipratropium bromide nasal spray 0.03% provides additional relief from rhinorrhea when combined with terfenadine in perennial rhinitis patients; a randomized, double-blind, active-controlled trial. Am J Rhinol. 1998;12(6):441–449.
   PubMedGoogle Scholar
• Kaiser HB, Findlay SR, Georgitis JW, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol. 1995;95(5 Pt 2):1128–1132.
   PubMed Web of Science ®Google Scholar
• Bush RK. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review. Treat Respir Med. 2004;3(1):45–57.
   PubMedGoogle Scholar
• Varney VA, Tabbah K, Mavroleon G, et al. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy. 2003;33(8):1076–1082.
   PubMed Web of Science ®Google Scholar
• Kim ST, Han DH, Moon IJ, et al. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy. 2010;24(4):271–275.
   PubMed Web of Science ®Google Scholar
• Solari JE, Loo J, Felices A, et al. Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic pharmacotherapy. Allergol Immunopathol (Madr). 2006;34(3):102–106.
   PubMedGoogle Scholar
• Rogala B, Markiewicz-Bendkowska IB, Brzoza Z, et al. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients. Rhinology. 2007;45(2):134–139.
   PubMed Web of Science ®Google Scholar
• Acquistapace F, Agostinis F, Castella V, et al. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial. Pediatr Allergy Immunol. 2009;20(7):660–664.
   PubMed Web of Science ®Google Scholar
• Braido F, Sclifo F, Ferrando M, et al. New therapies for allergic rhinitis. Curr Allergy Asthma Rep. 2014;14(4):422.
   PubMed Web of Science ®Google Scholar
• Lierl MB. New developments in the treatment of pediatric allergic rhinitis and conjunctivitis. Pediatr Ann. 2014;43(8):e192–e200.
   Google Scholar
• Braido F, Arcadipane F, Marugo F, et al. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14(2):168–176.
   PubMed Web of Science ®Google Scholar
• Mosges R. All of ARIA in one puff?. Int Arch Allergy Immunol. 2014;163(3):163–164.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Zhu Y, Steacy LM, et al. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125–133.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015;16(6):913–928.
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289 e10.
   Google Scholar
• Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324–332.
   PubMed Web of Science ®Google Scholar
• Leung DY, Szefler SJ, J. Associate Editors of the. The editors’ choice. J Allergy Clin Immunol. 2012;129(5):1216–1217.
   PubMedGoogle Scholar
• Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495–503.
   PubMed Web of Science ®Google Scholar
• Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179–185.
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Mosges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40–47.
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84–98.
   PubMed Web of Science ®Google Scholar
• Norman P. New H1/H3 antagonists for treating allergic rhinitis: WO2010094643. Expert Opin Ther Pat. 2011;21(3):425–429.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr., Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129(2):40912, 412 e1–e2.
   Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol. 2014;164(1):46–63.
   PubMed Web of Science ®Google Scholar
• Knothe S, Mutschler V, Rochlitzer S, et al. Local treatment with BPPcysMPEG reduces allergic airway inflammation in sensitized mice. Immunobiology. 2011;216(1–2):110–117.
   PubMed Web of Science ®Google Scholar
• Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011;20(7):981–986.
   PubMed Web of Science ®Google Scholar
• Henmar H, Lund G, Lund L, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol. 2008;153(3):316–323.
   PubMed Web of Science ®Google Scholar
• Fu Z, Lin X, Cai F, et al. The effects of subcutaneous allergen immunotherapy by Alutard SQ allergy vaccination in management of perennial allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26(16):744–746.
   PubMedGoogle Scholar
• Roger A, Depreux N, Jurgens Y, et al. A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy. Immun Inflamm Dis. 2014;2(2):92–98.
   PubMedGoogle Scholar
• Andersson M, Greiff L, Ojeda P, et al. Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review. Curr Med Res Opin. 2014;30(6):1131–1137.
   PubMed Web of Science ®Google Scholar
• Andersson M, Greiff L, Wollmer P. Effects of a topical microemulsion in house dust mite allergic rhinitis. Basic Clin Pharmacol Toxicol. 2011;108(2):146–148.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J. 2005;11(1):2.
   PubMedGoogle Scholar
• Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160–167.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717.
   PubMed Web of Science ®Google Scholar